- Home
- JSPR vs HOWL Comparison
JSPR vs HOWL Comparison
Compare JSPR & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- HOWL
- Stock Information
- Founded
- JSPR 2018
- HOWL 2017
- Country
- JSPR United States
- HOWL United States
- Employees
- JSPR N/A
- HOWL N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- HOWL Health Care
- Exchange
- JSPR Nasdaq
- HOWL Nasdaq
- Market Cap
- JSPR 47.3M
- HOWL 47.1M
- IPO Year
- JSPR N/A
- HOWL 2021
- Fundamental
- Price
- JSPR $3.15
- HOWL $1.36
- Analyst Decision
- JSPR Buy
- HOWL Strong Buy
- Analyst Count
- JSPR 12
- HOWL 3
- Target Price
- JSPR $31.67
- HOWL $8.33
- AVG Volume (30 Days)
- JSPR 1.5M
- HOWL 554.2K
- Earning Date
- JSPR 08-12-2025
- HOWL 08-07-2025
- Dividend Yield
- JSPR N/A
- HOWL N/A
- EPS Growth
- JSPR N/A
- HOWL N/A
- EPS
- JSPR N/A
- HOWL N/A
- Revenue
- JSPR N/A
- HOWL $1,143,000.00
- Revenue This Year
- JSPR N/A
- HOWL N/A
- Revenue Next Year
- JSPR N/A
- HOWL N/A
- P/E Ratio
- JSPR N/A
- HOWL N/A
- Revenue Growth
- JSPR N/A
- HOWL N/A
- 52 Week Low
- JSPR $2.27
- HOWL $0.60
- 52 Week High
- JSPR $26.05
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- JSPR 34.82
- HOWL 60.96
- Support Level
- JSPR $3.08
- HOWL $1.25
- Resistance Level
- JSPR $3.31
- HOWL $1.44
- Average True Range (ATR)
- JSPR 0.32
- HOWL 0.10
- MACD
- JSPR -0.04
- HOWL 0.02
- Stochastic Oscillator
- JSPR 34.11
- HOWL 68.89
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.